255 related articles for article (PubMed ID: 6541293)
1. Estrogen-stimulated prolactin synthesis in vitro. Classification of agonist, partial agonist, and antagonist actions based on structure.
Jordan VC; Lieberman ME
Mol Pharmacol; 1984 Sep; 26(2):279-85. PubMed ID: 6541293
[TBL] [Abstract][Full Text] [Related]
2. Structural requirements for the pharmacological activity of nonsteroidal antiestrogens in vitro.
Jordan VC; Lieberman ME; Cormier E; Koch R; Bagley JR; Ruenitz PC
Mol Pharmacol; 1984 Sep; 26(2):272-8. PubMed ID: 6482874
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
Murphy CS; Parker CJ; McCague R; Jordan VC
Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
[TBL] [Abstract][Full Text] [Related]
4. Regulation of prolactin synthesis in vitro by estrogenic and antiestrogenic derivatives of estradiol and estrone.
Jordan VC; Koch R
Endocrinology; 1989 Apr; 124(4):1717-26. PubMed ID: 2924721
[TBL] [Abstract][Full Text] [Related]
5. In vitro estrogenic actions in rat and human cells of hydroxylated derivatives of D16726 (zindoxifene), an agent with known antimammary cancer activity in vivo.
Robinson SP; Koch R; Jordan VC
Cancer Res; 1988 Feb; 48(4):784-7. PubMed ID: 3338076
[TBL] [Abstract][Full Text] [Related]
6. Hydroxylated polychlorinated biphenyls (PCBs) as estrogens and antiestrogens: structure-activity relationships.
Connor K; Ramamoorthy K; Moore M; Mustain M; Chen I; Safe S; Zacharewski T; Gillesby B; Joyeux A; Balaguer P
Toxicol Appl Pharmacol; 1997 Jul; 145(1):111-23. PubMed ID: 9221830
[TBL] [Abstract][Full Text] [Related]
7. Differential sensitivity of rat uterine growth and epithelium hypertrophy to estrogens and antiestrogens.
Branham WS; Zehr DR; Sheehan DM
Proc Soc Exp Biol Med; 1993 Jul; 203(3):297-303. PubMed ID: 8516342
[TBL] [Abstract][Full Text] [Related]
8. Ligand interaction at the estrogen receptor to program antiestrogen action: a study with nonsteroidal compounds in vitro.
Jordan VC; Koch R; Langan S; McCague R
Endocrinology; 1988 Apr; 122(4):1449-54. PubMed ID: 3345720
[TBL] [Abstract][Full Text] [Related]
9. Effects of 17 beta-estradiol, synthetic estrogens, and antiestrogens on prolactin secretion, nuclear translocation of pituitary estrogen receptor and on progesterone receptor levels in rat pituitary, hypothalamus and uterus.
Leibl H; Bieglmayer C; Spona J
Endocrinol Exp; 1981; 15(1):35-44. PubMed ID: 6971219
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018.
Jordan VC; Gosden B
Endocrinology; 1983 Aug; 113(2):463-8. PubMed ID: 6872937
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of basic side chain derivatives of Analog II as pure antiestrogens and antitumor agents.
Magarian RA; Avor KS; Overacre LB; Kunchandy J; Paxton TR
Anticancer Drug Des; 1995 Jun; 10(4):311-31. PubMed ID: 7786397
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release.
Kansra S; Yamagata S; Sneade L; Foster L; Ben-Jonathan N
Mol Cell Endocrinol; 2005 Jul; 239(1-2):27-36. PubMed ID: 15950373
[TBL] [Abstract][Full Text] [Related]
13. An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro.
Lieberman ME; Gorski J; Jordan VC
J Biol Chem; 1983 Apr; 258(8):4741-5. PubMed ID: 6833272
[TBL] [Abstract][Full Text] [Related]
14. The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells.
Maximov PY; Abderrahman B; Hawsawi YM; Chen Y; Foulds CE; Jain A; Malovannaya A; Fan P; Curpan RF; Han R; Fanning SW; Broom BM; Quintana Rincon DM; Greenland JA; Greene GL; Jordan VC
Mol Pharmacol; 2020 Jul; 98(1):24-37. PubMed ID: 32362585
[TBL] [Abstract][Full Text] [Related]
15. Guide-lines in the design of new antiestrogens and cytotoxic-linked estrogens for the treatment of breast cancer.
Leclercq G; Devleeschouwer N; Heuson JC
J Steroid Biochem; 1983 Jul; 19(1A):75-85. PubMed ID: 6887875
[TBL] [Abstract][Full Text] [Related]
16. Steroidal affinity labels of the estrogen receptor. 3. Estradiol 11 beta-n-alkyl derivatives bearing a terminal electrophilic group: antiestrogenic and cytotoxic properties.
Lobaccaro C; Pons JF; Duchesne MJ; Auzou G; Pons M; Nique F; Teutsch G; Borgna JL
J Med Chem; 1997 Jul; 40(14):2217-27. PubMed ID: 9216841
[TBL] [Abstract][Full Text] [Related]
17. Oestrogenic and antioestrogenic actions in a series of triphenylbut-1-enes: modulation of prolactin synthesis in vitro.
Jordan VC; Koch R; Mittal S; Schneider MR
Br J Pharmacol; 1986 Jan; 87(1):217-23. PubMed ID: 3955300
[TBL] [Abstract][Full Text] [Related]
18. Geometric isomers of substituted triphenylethylenes and antiestrogen action.
Jordan VC; Haldemann B; Allen KE
Endocrinology; 1981 Apr; 108(4):1353-61. PubMed ID: 6781873
[TBL] [Abstract][Full Text] [Related]
19. Estrogen induction of prolactin-producing pituitary tumors in the Fischer 344 rat: modulation by dietary-energy but not protein consumption.
Shull JD; Birt DF; McComb RD; Spady TJ; Pennington KL; Shaw-Bruha CM
Mol Carcinog; 1998 Oct; 23(2):96-105. PubMed ID: 9808163
[TBL] [Abstract][Full Text] [Related]
20. Opposing biological actions of antiestrogens in vitro and in vivo: induction of progesterone receptor in the rat and mouse uterus.
Campen CA; Jordan VC; Gorski J
Endocrinology; 1985 Jun; 116(6):2327-36. PubMed ID: 3996316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
